Ypsomed grows strongly in pharma customer business and continues to invest in the market development of the insulin pump

Ypsomed grows strongly in pharma customer business and continues to invest in the market development of the insulin pump

Press Releases Ypsomed Group

Burgdorf – In the financial year 2019/20, Ypsomed achieved consolidated sales of CHF 393.9 million (previous year: CHF 453.8 million). In the previous year, Ypsomed generated a turnover of 352.8 million in continuing operations. On this comparative basis, the result represents growth of CHF 41.0 million or 11.6 %. The operating result (EBIT) amounts to CHF 9.3 million. In the previous year, the discontinued operation contributed with CHF 61.9 million to the operating result of CHF 73.3 million. Net profit amounts to CHF 11.5 million (previous year: CHF 60.1 million).

Read more...

Ypsomed and Dexcom enter into partnership to drive closed loop system.

Ypsomed and Dexcom enter into partnership to drive closed loop system

Press Releases Ypsomed Group

Burgdorf/San Diego – Ypsomed (SWX:YPSN) and DexCom Inc. (NASDAQ:DXCM), the world's leading provider of continuous glucose monitoring (CGM) systems, announce their partnership to drive development of a hybrid closed loop system. The partnership is an important milestone in the further development of individualised diabetes therapy. In a first step, CGM data from Dexcom will be integrated into the mylife App from Ypsomed.

Read more...

Teva has announced the launch of AJOVY in an autoinjector device for the German market in March 2020.
AJOVY autoinjector

Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed

Press Releases Ypsomed Group

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25.

Read more...

COVID-19 business continuity

Press Releases Ypsomed Group

We are monitoring the global development after the outbreak of the Coronavirus very closely. Our highest priority is our business continuity and the reliable supply of our products as well as the safety of our employees. We can confirm that to date there is no impact on the supply of our products and that our production sites are fully operational.

Read more...

Delay in pump sales and strong growth in pharma customer business

Press Releases Ypsomed Group

Burgdorf – Ypsomed is recording weaker growth in the insulin pump business and is adjusting its approval strategy with the American FDA. In addition, Ypsomed is reducing its EBIT outlook for the current financial year 2019/20 to CHF 9 million due to one-time and temporary effects. Ypsomed confirms its mid-term EBIT target of CHF 100 million.

Read more...